Skip to main content
SpringerLink
Log in

Opinion and Evidence in Cancer

  • From the World Literature
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 1 Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected form over 1600 biomedical journals, this newsletter is produced by Adis International and is available in a variety of formats. Please contact your nearest Adis office for subscription details.

  2. Patients with metastatic breast cancer had complete or partial response to standard chemotherapy or had no evidence of disease after surgery or radiotherapy. Patients with high-risk breast cancer had 5 positive axillary nodes or inflammatory breast carcinoma and had undergone surgery and conventional chemotherapy.

  3. Additional systemic treatment was administered to 43% of women in the perioperative chemotherapy group and 42% of women in the surgery alone group. Postoperative radiotherapy was administered to 77 and 76% of patients in the perioperative chemotherapy and surgery alone groups, respectively.

  4. Costs included those for drug acquisition and hospitalisation, and were calculated from the perspective of the UK National Health Service.

  5. During the 18-year investigation period, treatment regimens consisted of 3 cycles of CHOP (comprising IV cyclophosphamide, IV doxorubicin and IV vincristine, plus oral prednisone, for 5 consecutive days, every 3 weeks), or close variations.

  6. Measured as months of estrogen pill use with or without progestogen.

  7. Patients received samarium-153 SM lexidronam 1, 3, 4.5, 6, 12, 19 or 30 mCi/kg.

References

Section 1

Section 2

  • Pérez-Gracia JL, Colomer R, Esteban E, et al. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a phase II multicentric trial. Cancer 2001 Nov 15; 92: 2508–16

    Article  PubMed  Google Scholar 

Section 3

  1. Noda K, Nishiwaki Y, Kawahara M, et al., for the Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 Jan 10; 346: 85–91

    Article  PubMed  CAS  Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, et al., for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10; 346: 92–8

    Article  PubMed  CAS  Google Scholar 

  3. Carney DN. Lung cancer — time to move on from chemotherapy. N Engl J Med 2002 Jan 10; 346: 126–8

    Article  PubMed  Google Scholar 

Section 4

  • van der Hage JA, van de Velde CJH, Julien J-P, et al. Improved survival after one course of perioperative chemotherapy in early breast cancer patients: long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer 2001 Nov; 37: 2184–93

    Article  PubMed  Google Scholar 

Section 5

  • Cummings SR, Duong T, Kenyon E, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002 Jan 9; 287: 216–20

    Article  PubMed  CAS  Google Scholar 

Section 6

  1. Cheson BD. CHOP plus rituximab: balancing facts and opinion. N Engl J Med 2002 Jan 24; 346: 280–2

    Article  PubMed  Google Scholar 

  2. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346: 235–42

    Article  PubMed  CAS  Google Scholar 

Section 7

  • Bebb JR, Logan RPH. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001 Dec; 15: 1843–9

    Article  PubMed  CAS  Google Scholar 

Section 8

  • Boccardo F, Rubagotti A, Amoroso D, et al., for the Italian Breast Cancer Cooperative Group. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study. J Clin Oncol 2001 Nov 15; 19: 4209–15

    PubMed  CAS  Google Scholar 

Section 9

  • Banfi A, Podestà M, Fazzuoli L, et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 2001 Nov 1; 92: 2419–28

    Article  PubMed  CAS  Google Scholar 

Section 10

Section 11

  • Plaxe SC, Blessing JA, Bookman MA, et al. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2002 Jan; 84: 32–5

    Article  PubMed  CAS  Google Scholar 

Section 12

  • Viens P, Chabannon C, Pouillard P, et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002 Jan 1; 20: 24–36

    Article  PubMed  CAS  Google Scholar 

Section 13

  • Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002 Jan 1; 20: 274–81

    Article  PubMed  CAS  Google Scholar 

Section 14

  • Hong R-L, Ting L-L, Ko J-Y, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001 Dec 1; 19: 4305–13

    PubMed  CAS  Google Scholar 

Section 15

  • Nicholls CJ, Cassidy J, Freemantle N, et al. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Drug Assess 2001; 4 Pt 4: 255–64

    Google Scholar 

Section 16

  • Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002 Jan 1; 20: 142–52

    Article  PubMed  Google Scholar 

Section 17

  1. Agteresch HJ, Rietveld T, Kerkhofs LGM, et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002 Jan 15; 20: 371–8

    Article  PubMed  CAS  Google Scholar 

  2. Jatoi A, Loprinzi CL. Adenosine triphosphate: does it help cancer patients get bigger and stronger? J Clin Oncol 2002 Jan 15; 20: 362–3

    Article  PubMed  Google Scholar 

Section 18

  • Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001 Dec 15; 98: 3846–8

    Article  PubMed  CAS  Google Scholar 

Section 19

  1. van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan 31; 415: 530–6

    Article  Google Scholar 

  2. Caldas C, Aparicio SAJ. The molecular outlook. Nature 2002 Jan 31; 415: 484–5

    Article  PubMed  CAS  Google Scholar 

Section 20

Section 21

  • Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002 Jan 1; 20: 197–204

    Article  PubMed  CAS  Google Scholar 

Section 22

  • Keating MJ, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002 Jan 1; 20: 205–13

    Article  PubMed  CAS  Google Scholar 

Section 23

  • Chen C-L, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA 2002 Feb 13; 287: 734–41

    Article  PubMed  CAS  Google Scholar 

Section 24

  • Gianni AM, Cortelazzo S, Magni M, et al., for the Michelangelo Cooperative. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002 Feb; 29 Suppl. 1: 10–3

    Article  Google Scholar 

Section 25

  • Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 2002 Jan 15; 20: 567–73

    Article  PubMed  CAS  Google Scholar 

Section 26

  • Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose Samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002 Jan 1; 20: 189–96

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Cancer. Am J Cancer 1, 153–163 (2002). https://doi.org/10.2165/00024669-200201020-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200201020-00009

Keywords

Search

Navigation